08:38 AM EDT, 06/23/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said on Monday it has halted its collaboration with Hims & Hers Health ( HIMS ) on the sale of weight loss drugs, including Wegovy.

The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform.

But Novo Nordisk ( NVO ) said direct access to the drug would no longer be available through Hims & Hers Health ( HIMS ) because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."

Hims & Hers did not immediately reply to MT Newswires' request for comment.

Hims & Hers shares were down by more than 21% in premarket trading, while Novo Nordisk ( NVO ) was down 6.5%.